Hospital & Healthcare Services

AGARWALEYE

Dr. Agarwal's Health Care Ltd.

Watchlist-worthy setup

Early Trend
Stage 2 VCP active Handle

Setup readiness

Early Trend

Pivot Levels
₹465.2-498.9
Support Level
₹472.6
Resistance
₹595.7
Risk Distance
5.3% to stop

Reference levels for educational study only. Not a recommendation to buy or sell.

RS
59.0
ADX
25.0
Vol
15.0

Swing Edge Intelligence

Structured setup analysis · research only

Setup status · Constructive setup

Structure shows workable momentum characteristics with selective risks to monitor.

Relative strength Neutral
Breakout readiness High
Accumulation Distribution pressure

Bullish factors

  • Reasonable 52w-high proximity (-15% below).
  • Price is approaching the pivot zone.
  • 1 prior pivot rejection in last 60d (-8 pts).
  • MACD positive and rising — confirmation only (no bonus).
  • RSI 68 — ideal setup zone.
  • Handle formation — consolidation after the prior advance.
  • Price has built a constructive advance from the 52-week low.
  • Distribution pressure visible across recent sessions.
  • Pocket pivot detected, but broader structure still shows distribution pressure.
  • Recent volume expansion — institutional participation may be returning.
  • Volume flow suggests quiet institutional accumulation.

Risk factors

Overall view

Localized accumulation signals (such as a pocket pivot) are present, but broader volume flow still reflects distribution pressure. Constructive setup — key momentum and institutional cues are broadly aligned for continued research.

Size this trade

Setup research

AGARWALEYE — trend, RS & risk snapshot (not a trade recommendation)

Signal · context · invalidation · risk · skip reasons — research only

Positives

Coiled at the pivot — breakout trigger is imminent

  • Handle formed after the prior advance
  • Confirmed Stage 2 uptrend

Flagged today

Context & regime

  • Market regime Mixed / range-bound
  • Trend stage Stage 2 — tradable
  • Sector Lagging (#40/40) — headwind
  • Relative strength Lagging (RS 59)
  • Trend strength Building (ADX 25)

Negatives

This idea is wrong below ₹472.6 (2.5% away)

Base / stop support breaks — the swing thesis is wrong below here

  • Stop / base low₹472.6
  • Pivot — failure re-entry below₹496.4

Risk distance

5.3% to stop
2.0× ATR
3.7× R:R
19.4% reward

Risk ≈ ₹26.31/share from entry ₹498.9.

No major skip flags detected from current scanner data.

Setup metrics Latest scan

AGARWALEYE Technical Analysis & Swing Setup

Grouped structure, momentum and risk from the latest research scan.

Volume Profile neutral
POC₹446.31
VAH₹467.53
VAL₹413.53
Vol above POC50.9%
Institutional Activity — Distribution
Avg cost basis₹473.82
Acc zone₹444.4–490.9
Accumulation Sessions2
CMF-0.12

Structure

Trend / stage
Stage 2 (Early)
Stage 2
Weekly trend
Above 30-wk MA (flat)
Above 30W
RS rank
59.0
Weakening
ADX
25.0
Building

Momentum

RSI
68.0
Strong
Recent move (10d / 20d)
+10.3% / +1.0%
Neutral
Volume quality
15.0
Thin
Relative strength
Neutral
Neutral

Risk

Failure risk
14.0
Low risk
ATR % / day
2.7%
Moderate
Distribution
1 day(s)
Neutral
Volatility
3 VCP
Contracting
More scanner fields
Sector RS 0.0%
Base 16w · 19.2%
VCP waves 3x
Vol dry-up No
Avg value ₹4.3 Cr
Failure flags Thin liquidity

AGARWALEYE Support & Resistance Levels

AI insights

AI Insights

Generated with AI

These insights are AI-generated to support your research process and should not be treated as investment advice or a recommendation to buy or sell securities.

Sign in to unlock AI Insights

Personalised swing trade analysis powered by Gemini AI

Pattern context 52w · setup · flow

52-week range

Stage-2 ideal band  ·  Early recovery

Pattern highlights

Loading…

Pattern signals from the latest scan

Smart money flow

Last 60 sessions · accumulation vs distribution

Loading…
Session flow 60 trading days
OBV trend On-balance volume · same window
·
Accumulation Distribution Neutral
Setup intelligence Overhead · VCP · radar · risk

Overhead supply

Resistance ceiling above current price

Loading…

Chase / failure risk

Honest read on exhaustion & extended moves

Loading…

Base / VCP coil

Depth, contractions & pivot distance

Loading…

Setup quality radar

Shape of the setup in one view

Loading…
Peer comparison Sector peers

Sector Peer Comparison

Loading sector peers…

Fetching peer data…
AGARWALEYE FAQ Common swing-trading questions

Frequently asked questions about AGARWALEYE

What are the screener observations for AGARWALEYE?

On Swing Edge's swing-setup framework, Dr. Agarwal's Health Care Ltd. (AGARWALEYE) currently grades B — workable setup. Coiled at the pivot — breakout trigger is imminent. Flagged today. This is educational research, not investment advice.

What are AGARWALEYE's support and resistance levels?

For AGARWALEYE, near-term support sits around ₹472.6 (the base/stop zone); overhead resistance is around ₹496.4 (the breakout pivot); the next resistance above is ₹595.7. This is educational research, not investment advice.

What is the breakout / pivot level for AGARWALEYE?

The breakout pivot for AGARWALEYE is around ₹496.4. Price is about 2.4% below the pivot and still building toward it. A breakout is typically confirmed on a close above the pivot with above-average volume. This is educational research, not investment advice.

Is AGARWALEYE above its 50-day and 200-day moving averages?

Yes — AGARWALEYE is in a confirmed Stage 2 uptrend, trading above its rising 50- and 200-day moving averages, the zone where swing setups tend to work best. This is educational research, not investment advice.

How strong is AGARWALEYE versus the market (RS rank)?

AGARWALEYE has a relative strength (RS) rank of 59 out of 100 versus the NSE universe, making it lagging the broader market on relative strength. Trend strength (ADX) reads 25, indicating a building trend. This is educational research, not investment advice.

Answers are generated from Swing Edge's latest scan data and are for research only — not investment advice.

Prices and day-change figures use the last daily close from scan data dated 2026-06-25 — not live intraday NSE quotes.